E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
The FDA approval is based on Phase 3 data, with 42% of adolescent patients with severe alopecia areata receiving Olumiant 4 mg achieving at least 80% scalp hair coverage at Week 36, compared with 5% on placebo.
imphoenix82
AbbVie has received approval from the European Commission (EC) for RINVOQ (upadacitinib; 15 mg and 30 mg, once daily) to treat adults and adolescents aged 12 years and older with severe alopecia areata (AA). Alopecia areata is an autoimmune disorder that causes unpredictable hair loss, ranging from small bald patches on the scalp to complete […]
imphoenix82
AbbVie has received a positive CHMP opinion for upadacitinib (RINVOQ) to treat adults and adolescents with severe alopecia areata and non-segmental vitiligo, with a final European Commission decision expected in the coming months.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
